Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
On Mar. 30, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) granted emergency use…
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
On Mar. 29, 2021, Moderna announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine…
On Mar. 29, 2021, Novavax, GSK and the UK Government Vaccines Taskforce announced an agreement in principle to…
On Mar. 29, 2021, CytoDyn announced that the Republic of the Philippines, Department of Health, Food and Drug…
On Mar. 23, 2021, CytoDyn announced the publication in the Journal of Translational Autoimmunity ‘Case study of a…
On Mar. 16, 2021, research from the WHO and partners showed that the COVID-19 pandemic was severely affecting…
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under…
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
On Mar. 11, 2021, Johnson & Johnson announced that the European Commission (EC) had granted a Conditional Marketing…
On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
On Mar. 10, 2021, Innovation Pharmaceuticals announced that a Machine Learning (Artificial Intelligence) model used to screen 1,482…